NCT02138734 2026-03-31A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerImmunityBio, Inc.Phase 1/2 Active not recruiting369 enrolled
NCT03022825 2025-10-16QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerImmunityBio, Inc.Phase 2/3 Active not recruiting190 enrolled 1 FDA